Liming Wang
Qingdao, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Clinical significance of microRNA-125b and its contribution to ovarian carcinogenesis.
Journal: Bioengineered
Published: August 27, 2020
SiRNA-Mediated RRM2 Gene Silencing Combined with Cisplatin in the Treatment of Epithelial Ovarian Cancer In Vivo: An Experimental Study of Nude Mice.
Journal: International journal of medical sciences
Published: February 11, 2019
Expression of microRNA-145, OCT4, and SOX2 in double primary endometrioid endometrial and ovarian carcinomas.
Journal: Histology and histopathology
Published: March 24, 2018
HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
Published: January 25, 2018
Cisplatin induced apoptosis of ovarian cancer A2780s cells by activation of ERK/p53/PUMA signals.
Journal: Histology and histopathology
Published: March 14, 2017
Knockdown of CIP2A sensitizes ovarian cancer cells to cisplatin: an in vitro study.
Journal: International journal of clinical and experimental medicine
Published: May 12, 2015
Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in ovarian cancer.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: March 08, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026